FLAMSA-BU regimen

WikiDoc Resources for FLAMSA-BU regimen
Articles
Most recent articles on FLAMSA-BU regimen Most cited articles on FLAMSA-BU regimen Review articles on FLAMSA-BU regimen Articles on FLAMSA-BU regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on FLAMSA-BU regimen Images of FLAMSA-BU regimen Photos of FLAMSA-BU regimen Podcasts & MP3s on FLAMSA-BU regimen Videos on FLAMSA-BU regimen
Evidence Based Medicine
Cochrane Collaboration on FLAMSA-BU regimen Bandolier on FLAMSA-BU regimen TRIP on FLAMSA-BU regimen
Clinical Trials
Ongoing Trials on FLAMSA-BU regimen at Clinical Trials.gov Trial results on FLAMSA-BU regimen Clinical Trials on FLAMSA-BU regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on FLAMSA-BU regimen NICE Guidance on FLAMSA-BU regimen NHS PRODIGY Guidance FDA on FLAMSA-BU regimen CDC on FLAMSA-BU regimen
Books
Books on FLAMSA-BU regimen
News
FLAMSA-BU regimen in the news Be alerted to news on FLAMSA-BU regimen News trends on FLAMSA-BU regimen
Commentary
Blogs on FLAMSA-BU regimen
Definitions
Definitions of FLAMSA-BU regimen
Patient Resources / Community
Patient resources on FLAMSA-BU regimen Discussion groups on FLAMSA-BU regimen Patient Handouts on FLAMSA-BU regimen Directions to Hospitals Treating FLAMSA-BU regimen Risk calculators and risk factors for FLAMSA-BU regimen
Healthcare Provider Resources
Symptoms of FLAMSA-BU regimen Causes & Risk Factors for FLAMSA-BU regimen Diagnostic studies for FLAMSA-BU regimen Treatment of FLAMSA-BU regimen
Continuing Medical Education (CME)
CME Programs on FLAMSA-BU regimen
International
FLAMSA-BU regimen en Espanol FLAMSA-BU regimen en Francais
Business
FLAMSA-BU regimen in the Marketplace Patents on FLAMSA-BU regimen
Experimental / Informatics
List of terms related to FLAMSA-BU regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

FLAMSA-BU regimen refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and busulfan used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).

Regimen

FLFludarabine

AMSAmsacrine

ACytarabine (Ara-C)

BUBusulfan

Indications

• Untreated, high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML)